Abstract
Background
Tumor necrosis factor inhibitor (TNFi) is recently reported to treat noninfectious uveitis (NIU) effectively. However, as a new kind of TNFi, golimumab is just on the market in China for several years, and its administration for NIU treatment lacks sufficient evidence. Therefore, the current study aimed to investigate the efficacy and safety of golimumab in refractory NIU patients.
Methods
Thirty NIU patients with 49 affected eyes refractory to conventional treatments (corticosteroids and immunosuppressive agents) were consecutively enrolled. They received treatment of TNFi (50 mg golimumab every 4 weeks) for at least 6 months. The anterior chamber cell grade, vitreous haziness grade, central macular thickness, and visual acuity were evaluated at baseline, month (M) 1, M3, and M6.
Results
After treatment, the anterior chamber cell grade declined from baseline (0.6 ± 0.7) to M6 (0.3 ± 0.5) (P < 0.001); the vitreous haziness grade decreased from baseline (1.2 ± 1.2) to M6 (0.4 ± 0.5) (P < 0.001); meanwhile, the central macular thickness also reduced from baseline (351.4 ± 90.8 μm) to M6 (271.8 ± 54.4 μm) (P < 0.001). In terms of visual acuity (LogMAR), it showed a declined trend from baseline (0.5 ± 0.3) to M6 (0.4 ± 0.2), but without statistical significance (P = 0.096). Subgroup analyses revealed that TNFi history related to decreased golimumab efficacy. In addition, 13.3% of patients had adverse events, including elevated liver enzymes (6.7%), fatigue (3.3%), and rash (3.3%).
Conclusion
Golimumab is effective and safe for refractory NIU treatment, while a large-scale trial is still needed for verification.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Enquiries about data availability should be directed to the authors.
References
Blauvelt A et al (2022) Long-term treatment patterns among patients with psoriasis treated with ixekizumab or adalimumab: a real-world study. J Drugs Dermatol 21:399–407. https://doi.org/10.36849/JDD.6336
Borras-Blasco J, Castera DE, Cortes X, Abad FJ, Rosique-Robles JD, Mallench LG (2015) Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. Int J Clin Pharmacol Ther 53:377–390. https://doi.org/10.5414/CP202171
Cordero-Coma M et al (2014) Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm 2014:717598. https://doi.org/10.1155/2014/717598
Curtis JR et al (2021) Incidence of infusion reactions and clinical effectiveness of intravenous golimumab versus infliximab in patients with rheumatoid arthritis: the Real-World AWARE Study. Rheumatol Ther 8:1551–1563. https://doi.org/10.1007/s40744-021-00354-4
Dave MB et al (2020) Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: an audit. Indian J Gastroenterol 39:426–434. https://doi.org/10.1007/s12664-020-01050-x
Ding X, Zhu R, Wu J, Xue L, Gu M, Miao L (2020) Early adalimumab and anti-adalimumab antibody levels for prediction of primary nonresponse in ankylosing spondylitis patients. Clin Transl Sci 13:547–554. https://doi.org/10.1111/cts.12738
Egwuagu CE, Alhakeem SA, Mbanefo EC (2021) Uveitis: molecular pathogenesis and emerging therapies. Front Immunol 12:623725. https://doi.org/10.3389/fimmu.2021.623725
Farvardin M, Afarid M, Shahrzad S (2012) Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 28:628–631. https://doi.org/10.1089/jop.2011.0199
Ferreira LB, Farrall AL, Furtado JM, Smith JR (2021) Treatment of noninfectious uveitis. Arq Bras Oftalmol 84:610–621. https://doi.org/10.5935/0004-2749.20220094
Forrester JV, Kuffova L, Dick AD (2018) Autoimmunity, autoinflammation, and infection in uveitis. Am J Ophthalmol 189:77–85. https://doi.org/10.1016/j.ajo.2018.02.019
Goupille P et al (2021) Real-life golimumab persistence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study GO-PRACTICE. Clin Exp Rheumatol. https://doi.org/10.55563/clinexprheumatol/ua3uqe
Guo X, Chen Z, Xing Y (2021) Immune-mediated uveitis and lifestyle factors: a review. Ophthalmic Res 64:687–695. https://doi.org/10.1159/000518496
Husni ME et al (2022) Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther 24:73. https://doi.org/10.1186/s13075-022-02753-6
Martin-Varillas JL et al (2021) Long-term Follow-up and optimization of Infliximab in refractory uveitis due to Behcet disease: National Study of 103 White Patients. J Rheumatol 48:741–750. https://doi.org/10.3899/jrheum.200300
Palmou-Fontana N et al (2018) Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol 36:652–657
Park SE, Jun JW, Lee DH, Lee SC, Kim M (2021) The effect of adalimumab in Korean patients with refractory noninfectious uveitis. Yonsei Med J 62:177–181. https://doi.org/10.3349/ymj.2021.62.2.177
Ritter E, Hirsch A, Isakov NF, Ron Y, Cohen NA, Maharshak N (2021) Higher maintenance adalimumab trough levels are associated with achievement of advanced remission targets in patients with inflammatory bowel disease. J Clin Gastroenterol 55:810–814. https://doi.org/10.1097/MCG.0000000000001435
Song H, Zhao C, Xiao J, Gao F, Li D, Zhang M (2022) The efficacy and safety of adalimumab in treating pediatric noninfectious chronic anterior uveitis with peripheral retinal vascular leakage: a pilot study. Front Med (lausanne) 9:813696. https://doi.org/10.3389/fmed.2022.813696
Suhler EB et al (2018) Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 125:1075–1087. https://doi.org/10.1016/j.ophtha.2017.12.039
Tosi GM et al (2019) Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol 37:680–683
Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C, Androudi S (2018) A focus on the epidemiology of uveitis. Ocul Immunol Inflamm 26:2–16. https://doi.org/10.1080/09273948.2016.1196713
Valdes LM, Sobrin L (2020) Uveitis therapy: the corticosteroid options. Drugs 80:765–773. https://doi.org/10.1007/s40265-020-01314-y
Valenzuela RA et al (2022) Definition of uveitis refractory to treatment: a systematic review in the absence of a consensus. Ocul Immunol Inflamm 30:174–179. https://doi.org/10.1080/09273948.2020.1793369
Wang CC et al (2022) Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: a two-center study in Taiwan. J Chin Med Assoc 85:175–182. https://doi.org/10.1097/JCMA.0000000000000673
Xiong A et al (2021) The efficacy and safety of infliximab in refractory noninfectious uveitis: a meta-analysis of observational studies. Front Pharmacol 12:620340. https://doi.org/10.3389/fphar.2021.620340
Yalcin Kehribar D, Gunaydin S, Ozgen M (2021) Infliximab therapy in parenchymal neuro-Behcet’s disease: a single-center experience. Int J Rheum Dis 24:1302–1307. https://doi.org/10.1111/1756-185X.14209
Yu J et al (2021) Effectiveness and safety of golimumab in patients with ulcerative colitis: a multicenter prospective postmarketing surveillance Study. Gut Liver. https://doi.org/10.5009/gnl210335
Funding
The authors have not disclosed any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have not disclosed any competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jin, Y., Lu, S., Lin, Y. et al. The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacol 30, 1363–1368 (2022). https://doi.org/10.1007/s10787-022-01019-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-022-01019-6